Signatera™ for Renal Cell Carcinoma (RCC)

Signatera™ is a personalized, tumor-informed ctDNA assay designed to detect molecular residual disease (MRD), refine post-nephrectomy risk stratification, and inform treatment decisions in patients with RCC.

Order Signatera™

Detect molecular recurrence in RCC

Up to ~40% of patients with RCC may experience recurrence following surgery.³ Conventional imaging and pathology may miss residual molecular disease.¹

Signatera™ is a personalized, tumor-informed ctDNA assay designed to detect molecular recurrence and support treatment decision-making in RCC.¹

Personalized ctDNA monitoring in RCC

ctDNA-positive patients

9x

more likely to recur vs, ctDNA-negative patients.¹

ctDNA-negative patients

93%

negative predictive value for recurrence-free survival.²

Longitudinal MRD testing

100%

sensitivity and specificity for recurrence detection.¹

Clinical evidence supporting Signatera™ in RCC

Signatera™ has demonstrated prognostic utility in localized and metastatic RCC for recurrence detection, risk stratification, and treatment-response monitoring.¹˒²

SGN_WB_MD_RenalCellCarcinoma_20260526_8023559_AccordionImage1_0

Localized RCC recurrence detection

ctDNA-positive patients had significantly shorter recurrence-free survival vs ctDNA-negative patients¹
Longitudinal ctDNA monitoring identified recurrence with 100% sensitivity and specificity among relapsed patients¹

SGN_WB_MD_RenalCellCarcinoma_20260526_8023559_AccordionImage2

Metastatic RCC treatment-response monitoring

ctDNA positivity was associated with shorter progression-free survival during surveillance¹
Serial ctDNA monitoring provided insight into disease progression and treatment response¹

SGN_WB_MD_RenalCellCarcinoma_20260526_8023559_AccordionImage3

Post-nephrectomy risk stratification

ctDNA status post-nephrectomy was prognostic for disease-free survival²
ctDNA-negative patients demonstrated a 93% negative predictive value for recurrence-free survival²

FAQs

What does a ctDNA-negative result mean after nephrectomy?

In MRD-GATE RCC, ctDNA-negative patients managed with observation had a 93% likelihood of remaining disease-free during follow-up.²

Can Signatera™ detect recurrence earlier than imaging?

Yes. In localized RCC, all recurrences were detected at or before clinical recurrence using longitudinal Signatera™ testing.¹

Is Signatera™ right for your patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Suri Y, Sudhaman S, Dwivedi B, et al. Clinical Performance of a Tumor-Informed Whole Genome-Based (WGS) ctDNA Assay for Recurrence Detection and Treatment Response Monitoring in Localized and Advanced/Metastatic Renal Cell Carcinoma (RCC). Presented at: ESMO Congress 2025; October 17–21, 2025; Berlin, Germany.

²Basu A, Sidhom F, Hwang C, et al. Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) — MRD-GATE RCC. Journal of the National Comprehensive Cancer Network. 2025;23(3.5):YIA25-001. doi:10.6004/jnccn.2024.7289.

³Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: 2022 Update. European Urology. 2022;82(4):399-410.